3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
7
Gastrointestinal
4
Thoracic
3
Dermatologic
3
Plasma cell
2
Other hematologic neoplasm
2
Lymphoid
2
Gynecologic
2
Genitourinary
2
Myeloid
1
Head & Neck
1
Endocrine
1
CNS
1
Conditions
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
3
Neoplasms
2
Hematologic Neoplasms
2
Thrombocytosis
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Lymphoproliferative Disorders
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Breast Neoplasms
1
Blast Crisis
1
Anemia
1
Interventions
Cyclophosphamide
35
Rituximab
33
venetoclax
24
ibrutinib
14
Vincristine
14
Prednisone
14
Doxorubicin
14
Gemcitabine
13
pembrolizumab
12
fludarabine
12
Bendamustine Hydrochloride
11
Etoposide
10
obinutuzumab
9
Filgrastim
9
Dexamethasone
9
Bortezomib
9
fludarabine phosphate
8
Mycophenolic Acid
8
Drug Therapy
8
ofatumumab
7
Whole-Body Irradiation
7
Sirolimus
7
Peripheral Blood Stem Cell Transplantation
7
Methotrexate
7
Busulfan
7
Therapeutics
6
Radiotherapy
6
Mesna
6
Lenalidomide
6
Ipilimumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
cobimetinib
×
Lymphoid
×
Clear all
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled